CCS
NVO

Concentric Capital Strategies’s Novo Nordisk NVO Stock Holding History

Concentric Capital Strategies’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49,781
Closed -$7.11M – 350
2024
Q2 		$7.11M Buy
49,781
+24,010
+93% +$3.18M 0.36% 61
2024
Q1 		$3.31M Buy
+25,771
New +$3.07M 0.19% 133

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Concentric Capital Strategies's NVO Position: Q3 2024 in Review

Concentric Capital Strategies sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 49,781 shares — an estimated $7.11M sold.

Concentric Capital Strategies first reported a position in NVO in Q1 2024 and held it in 2 quarters. The position peaked at $7.11M in Q2 2024. 1,785 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Concentric Capital Strategies reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Concentric Capital Strategies sold 49,781 Novo Nordisk shares in Q3 2024, an estimated $7.11M.
  • Concentric Capital Strategies first reported a position in Novo Nordisk in Q1 2024 and held it in 2 quarters.
  • Concentric Capital Strategies's Novo Nordisk position peaked at $7.11M in Q2 2024.
  • 1,785 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Concentric Capital Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.